loading...| Preferred Name |
Bevacizumab |
|
| Synonyms |
BEVACIZUMAB Bevacizumab Biosimilar CT-P16 Bevacizumab Biosimilar HLX04 Bevacizumab awwb BP102 Biosimilar Bevacizumab Bevacizumab-adcd Recombinant Humanized Anti-VEGF Monoclonal Antibody Bevacizumab Biosimilar QL1101 Bevacizumab Biosimilar MYL-1402O rhuMab-VEGF Bevacizumab Biosimilar CBT 124 Bevacizumab Biosimilar QL 1101 Bevacizumab Biosimilar GB-222 Bevacizumab Biosimilar LY01008 Anti-VEGF Humanized Monoclonal Antibody Bevacizumab Biosimilar BEVZ92 Bevacizumab Biosimilar FKB238 Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer Anti-VEGF rhuMAb Bevacizumab Biosimilar ABP 215 Bevacizumab Biosimilar Zirabev Bevacizumab Biosimilar SCT501 Bevacizumab-bvzr Bevacizumab Biosimilar MIL60 bevacizumab Bevacizumab Biosimilar HD204 Bevacizumab Biosimilar BAT1706 Bevacizumab Biosimilar IBI305 BAT1706 Biosimilar Anti-VEGF Monoclonal Antibody SIBP04 Bevacizumab Biosimilar RPH-001 Bevacizumab-awwb Bevacizumab Biosimilar Mvasi Bevacizumab Biosimilar BI 695502 ABP 215 Anti-VEGF Avastin BAT 1706 BAT-1706 BAT1706 BP102 CT-P16 HD204 MYL-1402O Mvasi QL1101 SCT501 SIBP 04 SIBP-04 SIBP04 Vegzelma Zirabev |
|
| Definitions |
A recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine. Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C2039 |
|
| Accepted_Therapeutic_Use_For |
Metastatic Colorectal Cancer, Non-small Cell Lung Cancer, glioblastoma; Metastatic Renal Cell Carcinoma; persistent, recurrent or metastatic cervical cancer; epithelial ovarian, fallopian tube, or primary peritoneal cancer |
|
| ALT_DEFINITION |
A drug used to treat several types of cancer, including certain types of colorectal, lung, breast, and kidney cancers and glioblastoma. It is also being studied in the treatment of other types of cancer. Avastin binds to vascular endothelial growth factor (VEGF) and may prevent the growth of new blood vessels that tumors need to grow. It is a type of antiangiogenesis agent and a type of monoclonal antibody. |
|
| CAS_Registry |
216974-75-3 |
|
| code |
C2039 |
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173381 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173383 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
| Contributing_Source |
CTRP FDA GDC HemOnc |
|
| DEFINITION |
A recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine. Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels. |
|
| Display_Name |
Bevacizumab |
|
| FDA_UNII_Code |
2S9ZZM9Q9V |
|
| FULL_SYN |
BEVACIZUMAB Bevacizumab Biosimilar CT-P16 Bevacizumab Biosimilar HLX04 Bevacizumab awwb BP102 Biosimilar Bevacizumab Bevacizumab-adcd Recombinant Humanized Anti-VEGF Monoclonal Antibody Bevacizumab Biosimilar QL1101 Bevacizumab Biosimilar MYL-1402O rhuMab-VEGF Bevacizumab Biosimilar CBT 124 Bevacizumab Biosimilar QL 1101 Bevacizumab Biosimilar GB-222 Bevacizumab Biosimilar LY01008 Anti-VEGF Humanized Monoclonal Antibody Bevacizumab Biosimilar BEVZ92 Bevacizumab Biosimilar FKB238 Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer Anti-VEGF rhuMAb Bevacizumab Biosimilar ABP 215 Bevacizumab Biosimilar Zirabev Bevacizumab Biosimilar SCT501 Bevacizumab-bvzr Bevacizumab Biosimilar MIL60 bevacizumab Bevacizumab Biosimilar HD204 Bevacizumab Biosimilar BAT1706 Bevacizumab Biosimilar IBI305 BAT1706 Biosimilar Anti-VEGF Monoclonal Antibody SIBP04 Bevacizumab Biosimilar RPH-001 Bevacizumab-awwb Bevacizumab Biosimilar Mvasi Bevacizumab Biosimilar BI 695502 ABP 215 Anti-VEGF Avastin BAT 1706 BAT-1706 BAT1706 BP102 CT-P16 HD204 MYL-1402O Mvasi QL1101 SCT501 SIBP 04 SIBP-04 SIBP04 Vegzelma Zirabev |
|
| Has_Target | ||
| Is_Value_For_GDC_Property | ||
| label |
Bevacizumab |
|
| Legacy Concept Name |
Bevacizumab |
|
| Maps_To |
Bevacizumab |
|
| NCI_Drug_Dictionary_ID |
43234 |
|
| NSC Number |
704865 |
|
| PDQ_Closed_Trial_Search_ID |
43234 |
|
| PDQ_Open_Trial_Search_ID |
43234 |
|
| Preferred_Name |
Bevacizumab |
|
| prefixIRI |
Thesaurus:C2039 |
|
| Semantic_Type |
Amino Acid, Peptide, or Protein Pharmacologic Substance |
|
| UMLS_CUI |
C0796392 |
|
| subClassOf |